Introduction {#sec1}
============

Breast cancer is the most common cancer and the leading cause of cancer death in females globally \[[@bib1]\]. It is classified into several molecular subgroups according to hormone receptor and HER2 status. Approximately 70% of breast cancers are estrogen receptor (ER) positive \[[@bib2]\], making ER is a key therapeutic target in ER+ breast cancer. Current endocrine therapies primarily target either the ER protein or the ligand binding domain of the receptor \[[@bib1], [@bib2], [@bib3]\], including (1) selective estrogen receptor modulators (SERMs) that directly inhibit the ER with mixed agonistic/antagonistic activities, such as tamoxifen, (2) selective ER degraders (SERDs), which are more potent antiestrogens and induce ER protein degradation, such as fulvestrant, and (3) aromatase inhibitors (AIs) that block the production of estrogen, such as letrozole or anastrozole \[[@bib3]\]. In early and metastatic breast cancer (MBC), endocrine therapies have been proven to improve survival and reduce recurrence \[[@bib4]\]. Nevertheless, endocrine resistance is inevitable after prolonged exposure to endocrine therapies \[[@bib3]\]. Over the past few years, various mechanisms of endocrine resistance have been discovered, such as loss of ER expression, deregulation of apoptosis and cell cycle signaling, and hyperactive receptor tyrosine kinase (RTK) \[[@bib5]\]. Recently, several preclinical studies have demonstrated that mutations in the ER encoding gene, *ESR1* are enriched in ER+ MBC patients, while rarely present in primary tumor tissue. *ESR1* mutations may account for resistance to aromatase inhibitors \[[@bib6], [@bib7], [@bib8], [@bib9]\]. However, we are lacking of studies to confirm whether ESR1 mutations could be used to provide a real-time dynamic monitoring of tumor evolution and therapeutic efficacy for ER+ MBC patients who are resistant to endocrine therapy. Therefore, in this study, we performed longitudinal genomic analyses of plasma samples from 45 MBC patients to explore potential clinical utility of tracking ESR1 mutations using circulating tumor DNA (ctDNA).

Materials and Methods {#sec2}
=====================

Patients and Samples {#sec2.1}
--------------------

A total of 45 MBC patients, treated at the Second Hospital of Dalian Medical University between January 2017 and February 2019, were enrolled in this study. We retrospectively collected the available paraffin-embedded tumor tissues, fresh frozen metastasis tissues, and cerebrospinal fluid (CSF); multiple plasma samples were also drawn for the ctDNA analysis. Basically, routine ctDNA analyses were performed approximately every 3 months during the follow-up period, along with tumor markers and/or imaging diagnosis. The clinicopathological features at the initial diagnosis of the enrolled patients are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Clinical Characteristics of the 45 Enrolled MBC PatientsTable 1VariablesNo. of Patients (%) (N = 45)**Age at Breast Cancer Diagnosis**Median (range)48(27--77)**Receptor Subtype**ER+/Her2−24(53.3%)ER+/Her2+5(11.1%)ER−/Her2+8(17.8%)Triple negative8(17.8%)**Histology Subtype (Primary tumor)**Invasive ductal36(80.0%)Invasive lobular2(4.4%)Other3(6.7%)Unknown4(8.9%)**Primary Clinical Stage**I3(6.7%)II11(24.4%)III19(42.2%)IV5(11.1%)Unknown7(15.6%)**Overall Survival**Median (range) month79.3(10.8--371.9)

Median age at primary breast cancer was 48 years (range 22--77 years). The primary breast cancer showed ductal (36, 80%), lobular (2, 4.4%) and other histological subtype (3, 6.7%), except four patients with unavailable tissues. At the clinical stages of primary tumors, 3 patients (6.7%) were categorized as stage I, 11 (24.4%) as stage II, 19 (42.2%) as stage III, and 5 (11.1%) as stage IV, but 7 patients were unknown. The median overall survival was 79.3 months (range, 10.8--371.9) in our cohort. Informed consent was obtained from all patients, and this study was approved by the Ethics Committee of the Second Hospital of Dalian Medical University.

Sample Preparation and Next Generation Sequencing {#sec2.2}
-------------------------------------------------

The paraffin-embedded FFEP white slices or rolled slices without gel and baking, at least 4 four tissue sections with tumor cell proportion of \>60% under the microscope, were screened. Five milliliters of peripheral blood was collected by EDTA blood collection tubes and then centrifuged within 1 h of collection at 1800×*g* for 10 min at 4≥°C or RT to remove blood cells. The supernatant containing the plasma was removed with special care taken as to not disturb the buffy coat. This was then centrifuged at 16,000×*g* for 10 min to remove any remaining cells. ctDNA was extracted from 2 ml plasma, by digestion in 100 μl proteinase K buffer for 10 min at 37 °C followed by purification with the NucleoSpin Plasma XS kit with modified protocols. The purified ctDNA is quantified by a PicoGreen fluorescence assay using the provided lambda DNA standards (Invitrogen). Then, library construction with the KAPA Hyper DNA Library Prep Kit, containing mixes for end repair, dA addition, and ligation, were performed in 96-well plates (Eppendorf). Dual-indexed sequencing libraries are PCR amplified for 4--7 cycles. Gene panel containing 425 breast cancer related genes was used to monitor the change trend of abundance fraction (Nanjing Geneq Tecnology Inc). The next generation sequencing (NGS), also known as large-scale parallel sequencing, was performed using Illumina Hiseq Technology (Nanjing Geneq Tecnology Inc).

Statistical Analysis {#sec2.3}
--------------------

The correlation of primary tumor tissue samples and paired plasma samples of ctDNA was assessed by the Fisher exact test. Overall survival (OS) was performed using the Kaplan Meier method and the long rank test. *P* value \<0.05 was considered statistically significant. All statistical analyses were two-sided and performed by GraphPad Prism 7 (GraphPad Software).

Results {#sec3}
=======

The Genomic Characteristics of MBC Patients in Our Cohort {#sec3.1}
---------------------------------------------------------

In our study, we retrospectively analyzed mutation profiles of paired plasma and tissue biopsy samples, falling into three distinct molecular subtypes including luminal (*n* = 29), HER2 positive (*n* = 8) and triple negative subtypes (*n* = 8) ([Table 1](#tbl1){ref-type="table"}). Six recurrent genes {TP53 (29/45, 64.4%), PIK3CA (21/45, 46.7%), ESR1 (9/45, 20%), ERBB2 (7/45, 15.6%), ATM (7/45, 15.6%), BRCA1 (6/45, 13.3%)} were mutated in more than 13% of patients. The landscape of these highly frequent molecular alterations detected by plasma ctDNA and paired tissue samples is shown for individual patients ([Figure 1](#fig1){ref-type="fig"}*A*). Two of them had no enough tissue because of inadequate tissue or biopsy contraindications.Figure 1(A) The landscape of high-frequency genomic alterations from 45 MBC patients detected in plasma and paired tissue samples is presented. The molecular subtyping and the patient ID numbers were at the up panel. For each gene, alteration in both tissue (down) and plasma (up) were presented, with percentage of prevalence shown on the left. (B) The percentage of mutations detected in our patient samples was compared with that reported in the cBioPortal (<https://www.cbioportal.org>). (C) The status of HER2 expression was measured by immunohistochemistry (IHC). HER2 gene amplification in tissue and ctDNA was detected by NGS.Figure 1

*ESR1* mutations were detected exclusively in the ER+ luminal subtypes, comprising 8 ER+/HER2− and 1 ER+/HER2+ patients ([Figure 1](#fig1){ref-type="fig"}*A*). The overall prevalence of *ESR1* mutations was 20%, consistent with Jeselsohn\'s research in 2013 (39/187, 21%) \[[@bib6]\]. In addition, *ERBB2* mutations were detected in seven samples, including 4 ER+/HER2− and 3 ER−/HER2+ patients ([Figure 1](#fig1){ref-type="fig"}*A*). Subsequently, we investigated whether the frequency of gene mutations in our cohort is similar with TCGA breast cancer database ([Figure 1](#fig1){ref-type="fig"}*B*). Our six recurrent genes presented significantly higher frequency ([Figure 1](#fig1){ref-type="fig"}*B*). This discrepancy may be partially because of the smaller population in our study.

Evaluation of the Consistency Between Paired Tissue and Plasma Samples {#sec3.2}
----------------------------------------------------------------------

Anti-HER2 therapies have changed the natural biology of HER2 positive breast cancer \[[@bib10]\]. Hence, HER2 assessment is very important in the clinic. Next, we compared the expression of HER2 detected by immunohistochemistry (IHC) and HER2 amplification detected by plasma or tissue-based NGS. In our cohort, 13 patients were found to overexpress HER2 by IHC ([Figure 1](#fig1){ref-type="fig"}*A* and *C*). Among them, five patients were ER+/HER2+, eight were ER−/HER2+, and one was removed from ER+/HER2+ as unavailable plasma tissue ([Figure 1](#fig1){ref-type="fig"}*C*). HER2 amplification was observed in 13(28.9%) tissues, 7(15.6%) plasma, and 1(2.2%) CSF samples. Of these, seven patients were HER2 amp positive for both tissue and liquid biopsy samples ([Figure 1](#fig1){ref-type="fig"}*C*). Furthermore, three samples negative for HER2 by IHC showed HER2 amplification by plasma or tissue-based NGS. Thus, tissue-based sequencing and plasma-based ctDNA might provide extra insights into HER2 status in MBC patients.

Overall, high concordance was seen in the mutation profiles between tissue and plasma samples (*R* = 0.96, *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}*A*).Figure 2(A) Correlation analysis between paired tissue and plasma samples. (B∼D) Overall survival analysis according to the state of TP53 mutation.Figure 2

TP53 Mutations is correlated with poor prognosis {#sec3.3}
------------------------------------------------

We next assessed whether recurrent gene mutations could predict prognosis in our study. We observed that MBC patients with TP53 mutations had significantly worse OS than the carriers of wild type alleles (*P* = 0.0094) ([Figure 2](#fig2){ref-type="fig"}*B*). In the luminal subtype or ER+/HER2− subgroup, the presence of TP53 mutations also demonstrated worse OS than wild type patients (*P* = 0.0135, *P* = 0.0299) ([Figure 2](#fig2){ref-type="fig"}*C* and *D*). However, in PIK3CA or ESR1 mutation subgroups, we did not observe any prognostic significance in our cohort, which may be related to the limited sample size in these subgroups.

The Clinical Characteristics of ESR1 Mutations in ER+ MBC {#sec3.4}
---------------------------------------------------------

In our study, *ESR1* mutations were detected in 20% (9/45) of MBC patients, and all of them were ER+ MBC ([Figure 1](#fig1){ref-type="fig"}*A*). We performed NGS on primary tumor biopsies collected before exposure to any therapies and paired metastatic biopsies in nine patients. To investigate whether ESR1 mutations were acquired after endocrine treatments, we found that 8 patients with ESR1 mutations received aromatase inhibitors before metastasis (except one with mutation in primary cancer) ([Figure 3](#fig3){ref-type="fig"}*A*). Of the 9 patients, *ESR1* Y537S (*n* = 5), Y537N (*n* = 1), and D538G (*n* = 2) mutations that located close to the hormone receptor were identified in post-AI samples. E380Q (another LBD mutation) was identified in one baseline and one post-AI tumor samples. We have also uncovered a few rare mutations (L345SfsX7, 24fs, G344delinsGC) in our cohort after SERD or SERM treatment in two patients (Patient 17 and 25) ([Figure 3](#fig3){ref-type="fig"}*A*). Overall, the mutation sites of ESR1 gene in our study were consistent with the TCGA database (Provisional cBioPortal, The Metastatic Breast Cancer Project) ([Figure 3](#fig3){ref-type="fig"}*B*). In addition, concurrent *ESR1* mutations were observed in Case29 (Y537N/Y537S/D538G) and Case17 (L345SfsX7/24fs/E380Q) during the course of treatment, which may be associated with the progression of disease and/or drug resistance ([Table 2](#tbl2){ref-type="table"}). These results suggested that *ESR1* mutations were recurrently enriched in ER+ MBC patients, but were rarely present in primary tumor tissues. The median time from AIs endocrine therapies to the first detection of ESR1 mutations was 39 months (95% CI 21.32--57.57) ([Figure 3](#fig3){ref-type="fig"}*A*). Detailed AI treatment history for all 9 patients is presented in [Table 2](#tbl2){ref-type="table"}.Figure 3(A) The clinical treatment courses of the nine patients with ESR1 mutations were summarized. (B) Region of ESR1 mutations detected in our samples (down panel) compared with that reported in the database (The Metastatic Breast Cancer Project, *n* = 237) (<https://www.cbioportal.org>) (up panel).Figure 3Table 2Clinical Characteristics of Nine ER-positive Metastatic Breast Cancer Patients with ESR1 MutationsTable 2Case No.Age at DiagnosisER/PR/HER-2Histologic TypeESR1-Mutation TypesPrevenient Endocrine TreatmentAI Treatment\
Overall Time (month)461+/+/+Invasive ductalE380Q-0759+/+/−UnknownY537SAI451753+/+/−Invasive ductalE380Q, 24fs, L345SfsX7AI, SERMs, SERDs342564+/−/-Invasive ductalG344 delins GCAI, SERDs602767+/+/−Invasive ductalD538GAI, SERMs, SERDs722934+/+/−Invasive ductalY537S, Y537N, D538GAI, SERMs, SERDs443156+/+/−Invasive lobularY537SAI, SERDs504066+/+/−Invasive ductalY537SAI54446+/+/−Invasive ductalY537SAI45

Monitoring ESR1 Mutations {#sec3.5}
-------------------------

ESR1 mutational status of five ER+ MBC patients was longitudinally monitored by ctDNA during the detailed clinical course. The tumor load was estimated by imaging using RECIST V.1.1. The serum tumor biomarker and ESR1 mutation levels were presented ([Figure 4](#fig4){ref-type="fig"}). Overall, dynamically monitoring ESR1 mutations by ctDNA might predict endocrine resistance of ER+ MBC, which was in consistent with dynamic change trend of serum tumor marker CA153/CA199/CA125 ([Figure 4](#fig4){ref-type="fig"}). The four ER+ MBC patients treated with the combination of everolimus showed longer PFS than other therapies without everolimus ([Figure 4](#fig4){ref-type="fig"}*A*--*D*). Strikingly, capecitabine alone also displayed excellent efficacy to against ESR1 mutation (ESR1.G344delinsGC) ([Figure 4](#fig4){ref-type="fig"}*E*). Together, monitoring ESR1 mutations by ctDNA might allow for cessation of ineffective endocrine therapies, and switch to other treatments without the need for tissue biopsy or before the emergence of metastatic disease.Figure 4(A∼E) Clinical timelines for the five representative ER-positive metastatic breast cancer patients harboring ESR1 mutations. The dynamic changes of ESR1 mutation levels were compared with serum tumor marker levels along with treatment.Figure 4

Discussion {#sec4}
==========

In this study, we performed NGS on plasma and paired tissue samples from MBC patients. Mutation profiles from tissue and plasma samples for these 45 patients were highly concordant. The overall survival seemed to be shorter in MBC patients with TP53 mutations than in TP53 wild type patients, which is in accordance with the analyses in the TP53 mutation-driven subgroup such as luminal subtype or ER+/HER2− subgroup. We also found acquired ESR1 mutations in eight ER+ MBC patients after AI therapy administered, and one primary ESR1 mutation in the baseline tumor tissue. We also demonstrated that dynamically monitoring the change of ESR1 mutations by ctDNA was an important biomarker, which could predict endocrine resistance of ER+ MBC in our study.

ESR1 mutation was first described in a metastatic breast cancer in 1997 \[[@bib11]\]. Recently, in several retrospective cohorts, ESR1 mutations have been reported in approximately 11%--55% of ER+ MBC patients treated with AIs, but were found to be extremely rare in primary breast cancers \[[@bib6], [@bib7], [@bib8],[@bib12], [@bib13], [@bib14]\]. In this study, we also observed the similar incidence rate of ESR1 mutations. In addition, we noticed that the mutation sites of ESR1 gene in our cohort were enriched on Y537 and D538, including missense mutations Y537S, Y537N, D538G, and E380Q. These common ESR1 mutations, located in ligand binding domain (LBD) of ER between amino acids 537--538, account for 74% of all mutations \[[@bib12]\]. In the PALOMA-3 trial, the ESR1 mutations in 360 ER-positive MBC patients were reported, including Y537S (23/360, 6%), Y537N (14/360, 4%), Y537C (5/360, 1%), and D538G (51/360, 14%) etc. Furthermore, the similar incidence of ESR1 mutations was also observed in the FERGI, the BOLERO-2 and the SoFEA study \[[@bib14]\]. Interestingly, breast cancer patients with the Y537S mutation have a shorter overall survival than patients with the D538G mutation \[[@bib15]\]. In this study, we also detected some rare mutations (L345SfsX7, 24fs, G344delinsGC) located outside the LBD\'s hotspot regions of the ESR1 gene, which has been scarcely described in previous studies or database ([Figure 3](#fig3){ref-type="fig"}*B*).

Previous research showed that acquired ESR1 mutations in ctDNA are rare before adjuvant AI treatments, but are frequently selected by AI therapies for metastatic disease, which provide molecular mechanism of resistance to AI therapy \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]\]. It is worth noting that how long to detect ESR1 mutations after AI exposure would be clinically useful. In this study, we observed that ESR1 mutations became detectable after receiving AIs endocrine therapies for approximately 39 months (95% CI 21.32--57.57) ([Figure 3](#fig3){ref-type="fig"}*A* and [Table 2](#tbl2){ref-type="table"}). Together, ESR1 mutations should be assessed before the progress of the disease but not after relapse.

We observed two cases with multiple ESR1 mutations (Case29: Y537N/Y537S/D538G, Case 17: L345SfsX7/24fs/E380Q) ([Table 2](#tbl2){ref-type="table"}) by longitudinal analysis of ctDNA. These different types of ESR1 mutations were sequentially acquired during the course of treatment, possibly reflecting tumor heterogeneity or the selection pressure evolution under endocrine treatment. Several longitudinal analyses of ctDNA indicated that ESR1 gene could acquire polyclonal mutations over the course of treatment, possibly reflecting differential response of individual ESR1 mutations to treatments \[[@bib23],[@bib24]\].

When everolimus was added to tamoxifen, exemestane, or fulvestrant, this resulted in an improved median PFS in ESR1-mutated patients, who previously received other kinds of therapy in our study. Indeed, the previous phase III BOLERO-2 study suggested that ESR1-mutated patients could still benefit from the addition of everolimus \[[@bib14],[@bib23]\]. In addition, the appearance of ESR1 mutations was proven to have prognostic and predictive significance of poorer outcome on subsequent endocrine treatment \[[@bib25], [@bib26], [@bib27]\]. Preclinical studies demonstrated the activation of the PI3K pathway after long-term estrogen deprivation of ER+ breast cancer cells, suggesting the effectiveness of combination of mTOR and ER inhibitions \[[@bib28]\]. Accordingly, it provides a theoretical basis for mTOR inhibitor in combination with endocrine therapy, which could significantly improve progression-free survival (PFS) of the MBC patients failing previous endocrine therapies \[[@bib29]\]. However, the interaction between the presence of ESR1 mutations and activation of the PI3K/AKT/mTOR still needs further research.

It has been shown that monitoring of mutations in ctDNA is a feasible and useful method to predict potential disease progression in MBC patients \[[@bib30],[@bib31]\]. Some researchers monitored treatment response over time using NGS-based approach, and found that dynamic of ctDNA levels was correlated with changes of CA15-3 or circulating tumor cells in advanced breast cancer patients \[[@bib32], [@bib33], [@bib34]\]. In this study, our results further demonstrated that dynamically monitoring the change of ESR1 mutations by ctDNA could predict endocrine resistance of ER+ MBC. However, our study was a retrospective, single-institute study with a relatively small patient number, thus a larger sample study is required to confirm our findings.
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